ESMO Congress | Conference

Frontline Osimertinib Doubles PFS for EGFR+ NSCLC

September 9th 2017

Frontline osimertinib improved median progression-free survival by 18.9 months, representing a 54% reduction in the risk of progression or death compared with standard therapy for patients with EGFR-mutant non–small cell lung caner.

Taselisib, Letrozole Combination Active for ER+, HER2- Early Breast Cancer

September 8th 2017

Taselisib added to standard letrozole (Femara) improved the objective response rate compared to letrozole with a placebo in postmenopausal women with estrogen receptor-positive and HER2-negative early breast cancer.

Alectinib Highly Effective for ALK+ NSCLC With CNS Metastases

September 8th 2017

Treatment with alectinib (Alecensa) demonstrated promising efficacy for patients with ALK-translocated non–small cell lung cancer with central nervous system metastases in both the first- and second-line setting.

Maintenance Rucaparib Highly Effective Across Ovarian Cancer Subtypes

September 8th 2017

Maintenance treatment with the PARP inhibitor rucaparib improved median progression-free survival by 11.2 months compared with placebo for patients with BRCA-mutant platinum-sensitive ovarian cancer.

Dr. Mirza on Impact of Niraparib in Ovarian Cancer

November 30th 2016

Mansoor Raza Mirza, MD, chief oncologist at Rigshospitalet, Copenhagen, Denmark, discusses niraparib in patients with platinum-sensitive recurrent ovarian cancer

Lead Researcher Discusses Promising Antibody-Drug Conjugate for Ovarian Cancer

October 25th 2016

Results from an expansion cohort of a preliminary clinical trial have shown encouraging activity for a novel antibody-drug conjugate in patients with heavily pretreated advanced ovarian cancer.

Dr. Choueiri on Ongoing Trials of Immunotherapy in RCC

October 20th 2016

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses some of the ongoing trials evaluating different immunotherapy agents in renal cell carcinoma.

Dr. Patrick M. Forde on Neoadjuvant Nivolumab in NSCLC

October 20th 2016

Patrick M. Forde, MBBCh, assistant professor of oncology, Johns Hopkins Hospital, discusses a study presented at ESMO 2016 on neoadjuvant nivolumab, in early stage resectable non-small-cell lung cancer (NSCLC).

Novel HER2-Targeting Antibody-Drug Conjugate Shows Broad Antitumor Activity

October 20th 2016

A novel HER2-targeting antibody-drug conjugate showed promising antitumor activity across multiple tumor types, including HER2-postive breast cancer.

Long-Term Follow-Up Supports Frontline Dabrafenib/Trametinib in Melanoma

October 20th 2016

Co-inhibition of BRAF and MEK pathways with dabrafenib and trametinib continued to be superior to sole BRAF inhibition with vemurafenib in patients with unresectable metastatic melanoma at 3 years.

Niraparib Expected to Change Practice in Ovarian Cancer

October 19th 2016

The PARP1/2 inhibitor niraparib significantly improved progression-free survival in patients with platinum-sensitive recurrent ovarian cancer.

Streamlined BRCA Testing Program Shows Promise in Ovarian Cancer

October 19th 2016

An interim analysis of an ongoing study showed potential for reducing time and improving acceptance of testing and counseling for patients with ovarian cancer.

Combinations With Abemaciclib Show Long-Term Disease Control in Advanced Breast Cancer

October 19th 2016

Abemaciclib plus tamoxifen, trastuzumab, or one of many endocrine-based therapies demonstrated significant antitumor activity and clinical benefit in patients with advanced breast cancer.

Controversy Remains on Addition of VEGF Inhibition Before Interval Debulking in Ovarian Cancer

October 19th 2016

The addition of bevacizumab to neoadjuvant platinum-based chemotherapy led to a significantly increased rate of complete resection at interval debulking in advanced ovarian cancer.

Nivolumab/Cabozantinib Combo Shows Promise in GU Cancers

October 18th 2016

Cabozantinib plus nivolumab demonstrated promising activity in the second-line setting and beyond at all dose levels tested in patients with advanced/refractory genitourinary cancers.

Dr. Jasgit Sachdev on Antibody-Drug Conjugate PF-06647020 in Ovarian Cancer

October 18th 2016

Jasgit Sachdev, MD, clinical associate professor at Translational Genomics Research Institute, discusses a phase I study of PF-06647020, an antibody-drug conjugate targeting protein tyrosine kinase 7 (PTK7) in patients with platinum-resistant ovarian cancer.

Dr. Hortobagyi on MONALEESA-2 Trial Results in HR+ Breast Cancer

October 18th 2016

Gabriel N. Hortobagyi, MD, professor of Medicine at The University of Texas MD Anderson Cancer Center, discusses findings from the phase III MONALEESA-2 trial, which looked at the addition of the CDK 4/6 inhibitor ribociclib to endocrine therapy in postmenopausal women with hormone receptor (HR)-positive metastatic breast cancer.

Dr. Jean-Yves Blay on Eribulin in Leiomyosarcoma

October 18th 2016

Jean-Yves Blay, MD, PhD, professor of medicine at the Université Claude Bernard, Lyon, France, and the scientific director of the Canceropole Lyon Rhône Alpes, discusses a subgroup analysis of leiomyosarcoma patients from a phase III study of eribulin compared to dacarbazine (DTIC) in patients with advanced liposarcoma or leiomysosarcoma.

Adding Bone Drugs to Radium-223 May Enhance Benefit in mCRPC

October 17th 2016

Men with bone-metastatic castration-resistant prostate cancer appeared to derive additional benefits from treatment with radium-223 with concomitant bone-targeted therapies, according to data from an extended-access program.

No PFS Benefit in Recurrent Head and Neck Cancer With Addition of Immunotherapy

October 12th 2016

Adding a Toll-like receptor 8 agonist to standard care for patients with recurrent or metastatic squamous cell carcinoma of the head and neck failed to improve progression-free survival.